It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Drug-drug interactions (DDIs) can compromise safety, efficacy, and regulatory success. At Sygnature Discovery, we combine validated in vitro assays with expert interpretation to reduce risk and accelerate your path to the clinic.
Polypharmacy is increasing worldwide, driven by aging populations and combination therapies. This makes DDIs a growing regulatory concern, highlighted in ICH M12 (2024). Enzyme inhibition can raise systemic exposure, while induction may lower therapeutic concentrations or generate harmful metabolites.
Comprehensive in vitro evaluation is essential to anticipate these risks. We assess your compound as both a precipitant (inhibitor or inducer of enzymes or transporters) and an object (substrate of metabolic or transporter pathways). This data informs clinical risk, guides dose adjustments, and supports regulatory approval.
Our Drug-Drug Interaction Expertise
Combined with expert study design and interpretation, our DDI services support confident decision-making and accelerate progression to the clinic.
CYP Reaction Phenotyping
Identify the specific cytochrome P450 (CYP450) enzymes responsible for metabolizing your compound. This insight predicts interaction risk and variability, enabling rational clinical development and informed regulatory decisions.
Assess whether your compound upregulates CYP enzyme expression through transcriptional activation. Using RT-qPCR for mRNA measurement, we provide sensitive, quantitative data to flag induction risks early and support metabolic liability evaluations.
Determine if your compound competitively inhibits CYP enzymes using isoform-specific probe substrates. These studies are critical for anticipating DDIs and shaping development strategies.
Time-Dependent CYP Inhibition (IC50 Shift) and Kinact/Ki
Quantify the kinetics of mechanism-based CYP inhibition to predict in vivo relevance. Kinact and Ki values inform PBPK modeling and regulatory decisions, ensuring your program moves forward with confidence.
Explore cutting-edge insights into small molecule innovations driving obesity and weight…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
